Press

The Bright Pink PROACT Program at Stanford University.

https://www.brightpink.org/legacy-investment

In 2024, Bright Pink made a $3.5 million legacy gift to establish the Bright Pink Preventive Risk Outreach And Cascade Testing (PROACT) Program at Stanford Medicine.

Led by Stanford physicians Dr. Allison Kurian and Dr. Jennifer Caswell-Jin, in collaboration with the University of Michigan, the Bright Pink PROACT Program aims to democratize access to cascade testing.

This type of genetic testing, which identifies hereditary mutations like BRCA1 and BRCA2 and extends testing to family members, holds enormous potential to save lives from breast and ovarian cancer, yet remains significantly underutilized, with only one-third of those at risk taking action.